论文部分内容阅读
目的:研究肝细胞癌(hepatocellular carcinoma,HCC)经导管肝动脉化疗栓塞(transcatheter arterial chemoemboli-zation,TACE)后残癌组织细胞黏附分子CD44v6和ICAM-1(intercelluar adhesion molecule-1,ICAM-1)的表达情况。方法:经病理证实的HCC 50例,包括单纯手术切除30例(对照组),TACE术后行Ⅱ期手术切除20例(TACE组)。TACE组患者术前接受1~2次不等的TACE治疗,均按统一规范标准给予化疗药物灌注+栓塞治疗。对标本行免疫组织化学PV-9000染色,其中TACE组取病灶边缘残存肿瘤部分,检测肿瘤组织CD44v6和ICAM-1的表达,将两组结果进行对照分析。结果:对照组和TACE组CD44v6和ICAM-1均有不同程度的表达。对照组CD44v6表达阳性22例(22/30,73.33%),TACE组CD44v6表达阳性13例(13/20,65%),两者间无显著性差异(P>0.05);对照组ICAM-1表达阳性19例(19/30,63.33%),TACE组ICAM-1表达阳性12例(12/20,60%),两者间亦无显著性差异(P>0.05)。对照组和TACE组中CD44v6和ICAM-1表达间均呈正相关(P<0.05)。结论:TACE术后残癌组织CD44v6和ICAM-1仍有较高的表达,TACE并不能有效降低肝癌组织CD44v6和ICAM-1的表达;两者表达呈正相关。
OBJECTIVE: To study the expression of CD44v6 and ICAM-1 (ICAM-1) in human hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) The expression of the situation. Methods: HCC was confirmed by pathology in 50 cases, including 30 cases of simple surgical resection (control group) and 20 cases of TACE (TACE group). Patients in TACE group received 1 ~ 2 times of TACE preoperatively, and all were given chemotherapeutic drug infusion and embolization according to standardized norms. The specimens were stained with immunohistochemistry PV-9000. TACE group was used to detect the residual tumor in the margins of the lesion. The expression of CD44v6 and ICAM-1 in the tumor tissues was detected. The results of the two groups were compared. Results: CD44v6 and ICAM-1 in control group and TACE group all expressed in different degree. There were 22 cases (22/30, 73.33%) positive for CD44v6 in the control group and 13 cases (13/20, 65%) in the TACE group, there was no significant difference between the two groups (P> 0.05) The expression of ICAM-1 in TACE group was 12 (12/20, 60%) positive (19/30, 63.33%). There was no significant difference between the two groups (P> 0.05). There was a positive correlation between the expression of CD44v6 and ICAM-1 in control group and TACE group (P <0.05). CONCLUSION: TACE still has high expression of CD44v6 and ICAM-1 in residual cancer tissues. TACE can not effectively reduce the expression of CD44v6 and ICAM-1 in HCC tissues. There is a positive correlation between them.